Ken Griffin Concert Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$4.34 - $5.84 $89,404 - $120,304
-20,600 Reduced 20.56%
79,600 $464,000
Q3 2022

Nov 14, 2022
BUY
$4.27 - $7.2 $227,590 - $383,760
53,300 Added 113.65%
100,200 $671,000

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About CONCERT PHARMACEUTICALS, INC.

CNCE Quotes by TradingView
  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email